As much as 10 analysts have advised buy on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with an average broker rating of 1.55. Zacks research analysts are highly optimistic on the shares and has given it a short term rating of 1, indicating that it is a Strong Buy.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) should head towards $265 per share according to 10 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $141 per share. The higher price estimate target is at $310 according to the Analysts.
Company has received recommendation from many analysts. BTIG Research initiates coverage on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $275 per share. The rating by the firm was issued on July 20, 2015.